News

  • Reset

Mayne Pharma appoints new CEO

28 Sep 2022

Mayne Pharma Group Limited is pleased to announce it has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer and Managing Director effective 1 October 2022. This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.

Learn more

Mayne Pharma Logo

Non Executive Director appointment and retirement

31 Aug 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr David Petrie, has accepted an invitation to join the Board of Mayne Pharma, effective 1 September 2022.

Learn more

Mayne Pharma 2022 Full Year Results Media Release

26 Aug 2022

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, we reported annual revenue growth for the first time in five years. Excluding retail generics, the remaining businesses which represent more than 80% of reported gross profit grew 27% on the prior corresponding period (pcp).

Learn more

Mayne Pharma CEO announces plan to retire

19 Aug 2022

Mayne Pharma Group Limited advises that Chief Executive Officer (CEO) Scott Richards has announced his intention to retire following a decision by the Board to relocate the CEO role to the US on a permanent basis. Mr Richards is unable to make this commitment and wants to return to Australia for personal reasons.

Learn more

Mayne Pharma announces sale of Metrics Contract Services

10 Aug 2022

Mayne Pharma today announced that it has entered into an agreement with Catalent to sell Metrics Contract Services for a total cash consideration of US$475 million (~A$679 million)

Learn more

Hands holding a Nuvaring

Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring

8 Aug 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring

Learn more

NEXTSTELLIS® oral contraceptive nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent

2 Aug 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent.

Learn more

Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS®

29 Jul 2022

Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.

Learn more

Contraceptive Packet

NEXTSTELLIS® oral contraceptive now available in Australia

26 Jul 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets), a first-of-its kind oral contraceptive with a novel estrogen is now available in Australia.

Learn more